
Analysis: RFK Jr. made some promises on vaccines to get confirmed. Is he breaking them?
The Trump era is rife with Republicans who abandon their principles in the name of toeing Donald Trump's line. But few have gambled with those principles recently like Louisiana Republican Sen. Bill Cassidy.
The chairman of the Senate Health, Education, Labor and Pensions Committee in February played the pivotal role in confirming a longtime purveyor of vaccine misinformation, Robert F. Kennedy Jr., as Health and Human Services secretary.
Cassidy did so despite often citing how 30 years of practicing medicine taught him how crucial vaccines are – and despite his very public reservations about Kennedy's views and motivations on the subject. He also did so at a time when vaccine skepticism has risen sharply on the right, meaning Cassidy's strongly held beliefs were already losing ground.
At Kennedy's confirmation hearing, Cassidy recalled loading an 18-year-old woman who had hepatitis B onto an ambulance so she could get an emergency liver transplant.
'And as she took off, it was the worst day of my medical career, because I thought $50 of vaccines could have prevented this all,' Cassidy said. 'That was an inflection point in my career.'
Cassidy, who faces reelection and likely a primary challenge in 2026, ultimately gave Kennedy a decisive vote, after obtaining what the senator cast as a series of vaccine-related concessions.
But pretty much ever since then, Kennedy has tested the spirit of that agreement, if he hasn't violated it outright.
Most recently, that took the form of Kennedy on Monday removing all 17 members of an expert panel of advisers that guides the federal government's vaccine recommendations.
Many immediately cast this as contrary to what Kennedy promised Cassidy. It's not quite so simple, for reasons we'll get to. But plenty of other actions could fit into that category.
For his part, Cassidy on Monday would not tell CNN whether he regrets his vote for Kennedy.
Last month, the senator said Kennedy had 'lived up to' the agreement. But at other times, he has taken issue with Kennedy's actions.
It's worth a review of what Cassidy said back then – and since.
Cassidy laid out the conditions during a speech on the Senate floor.
In those February remarks, Cassidy cited the same vaccine advisory panel Kennedy just cleared out.
'If confirmed, he will maintain the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices' recommendations without changes,' Cassidy said, according to video of his remarks.
An old transcript of Cassidy's speech on his own website omitted the word 'recommendations,' leading Kennedy's critics on Monday to accuse him of breaking his word by changing the makeup of the committee itself. But Cassidy's comments pertained to the committee's recommendations. (CNN has reached out to Cassidy's office about the transcript.)
Cassidy in an X post Monday expressed concern about what comes next. He cited a 'fear' that 'ACIP will be filled up with people who know nothing about vaccines except suspicion.'
'I've just spoken with Secretary Kennedy, and I'll continue to talk with him to ensure this is not the case,' he added.
He declined to go further when pressed by CNN's Manu Raju.
Cassidy also said in his February speech that Kennedy had 'committed that he would work within current vaccine approval and safety monitoring systems and not establish parallel systems.'
But just in the past two weeks, Kennedy announced changes to the CDC's recommended vaccine schedules without ACIP's input.
'CDC will not remove statements on their website pointing out that vaccines do not cause autism,' Cassidy said in his speech.
There is no evidence that the CDC has done this. But Kennedy has taken actions that seem geared toward his longstanding and debunked linking of vaccines to autism, which Cassidy took exception to at Kennedy's confirmation hearing.
Most recently, this took the form of launching a 'massive testing and research effort' to find the causes of autism, which critics worry will be geared toward vaccines. And indeed, CNN previously reported HHS had asked the CDC to study vaccines and autism, despite strong evidence there's no link between the two.
This is one area where Cassidy has expressed reservations.
'I'll point out that has been clearly laid to rest,' the senator said in April of the supposed link between vaccines and autism, according to The Advocate. 'The more resources we put towards that, we are not putting towards actually finding out what is the cause of autism.'
Finally, Cassidy's floor speech suggested Kennedy had provided assurances that he wouldn't use his position to 'wrongfully' create suspicion about vaccines.
'I will watch carefully for any effort to wrongfully sow public fear about vaccines [through] confusing references of coincidence and anecdote,' Cassidy said. 'But my support is built on assurances that this will not have to be a concern …'
There is no question Kennedy as HHS secretary has said many things that could undermine confidence in vaccines – often using misinformation.
Amid a measles outbreak in Texas, Kennedy wasn't quick to explicitly recommend the measles-mumps-rubella vaccine, while floating unconventional treatments like vitamin A in ways that experts worried would discourage vaccinations.
He also made a series of claims about the MMR vaccine that experts reject. These have included that it contains 'fetal debris' and that it 'was never safety tested.'
He has also claimed that no childhood vaccine except the Covid-19 vaccine has been fully tested against placebos. But that's not true — something Cassidy pointed out in perhaps the most significant example of him calling out Kennedy.
After Kennedy made the claim at a hearing last month, Cassidy returned to the hearing to correct him.
'The secretary made the statement that no vaccines except for Covid have been evaluated against placebo,' Cassidy said. 'For the record, that's not true. The rotavirus, measles and HPV vaccines have been, and some vaccines are tested against previous versions. So, just for the record to set that straight,' Cassidy said.
It was the kind of claim that might lead one to wonder whether the guy you elevated to such a powerful position was actually living up to the agreement that got him there.
Cassidy doesn't seem willing to go there yet. But all signs are Kennedy is going to continue making him second-guess his choices.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Factbox-Breakdown of U.S. tariffs on China since Trump's first term
BEIJING (Reuters) -Billions of dollars of Chinese goods have been impacted by additional U.S. tariffs since 2018, initially under the first Donald Trump presidency and later under the Biden administration. Returning to the White House this year, Trump has imposed even more duties on China. The U.S. tariffs range from those imposed under Section 301 of its trade act due to what Washington claims are unfair Chinese trade practices, to duties under Section 232 levied for national security reasons. This year, Trump has imposed another 20% levies on all Chinese goods, saying Beijing has not done enough to stop the flow of fentanyl into the United States. So-called reciprocal tariffs, under which the U.S. will match duties imposed by other countries, have also been levied in a bid to rebalance trade flows. Below are the U.S. tariffs on China effective as of June 12, 2025: Tariff Rate Products Effective date Reciprocal 10% All Paused for 90 days until Aug 10, 2025 Fentanyl 20% All Mar 4, 2025 Section Up to List 1: Pharmaceuticals, July 6, 2018 301 25% iron and steel, aluminium, vehicles and aircraft, medical or surgical instruments and apparatus and more. List 2: Vehicles, Aug 23, 2018 railway or tramway locomotives, aircraft and their parts, medical or surgical instruments and apparatus and more. List 3: Prepared May 10, 2019 foodstuffs, beverages, mineral products, fertilizers, wood products, textiles, precious and base metals, vehicles, aircraft, vessels, machinery and mechanical appliances and more. List 4A: Prepared Feb 14, 2020 foodstuffs, beverages, mineral products, fertilizers, footwear, wood products, ceramic products, glass, textiles, precious and base metals, machinery and mechanical appliances, vehicles, aircraft, vessels, art, antiques and more. In September 2019, the U.S. imposed 15% tariffs on more than $120 billion of Chinese goods under Section 301, which it then halved to 7.5% less than six months later. The 25% U.S. tariffs on $250 billion of Chinese goods under the earlier List 1-3 remain unchanged. In September 2024, the U.S. Trade Representative under the Biden administration announced additional tariffs of 25-100% on 14 product groups following a four-year review of the Section 301 tariff actions. The levies were imposed on strategic Chinese sectors or sectors where the United States has made significant domestic investments. Additional tariffs on goods under Section 301: Effective date EVs 100% Sep 27, 2024 Solar cells, syringes and 50% needles Non-lithium-ion battery parts, 25% lithium-ion electrical vehicle batteries, other critical minerals, ship-to-shore cranes, steel and aluminium products, facemasks Semiconductors 50% Jan 1, 2025 Lithium-ion non-electrical 25% Jan 1, 2026 vehicle batteries, medical gloves, natural graphite, permanent magnets In addition to the above duties, the first Trump administration in 2018 imposed a range of tariffs under Section 232 aimed at restricting goods deemed a threat to national security, including all aluminium and steel imports, shutting most Chinese suppliers out of the U.S. market. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Boston Globe
22 minutes ago
- Boston Globe
Mass. needs competitive pay for defense lawyers
Get The Gavel A weekly SCOTUS explainer newsletter by columnist Kimberly Atkins Stohr. Enter Email Sign Up Legislators ought to listen to the committee. Ensuring that there are enough lawyers to uphold the constitutional right to representation enshrined in the Sixth Amendment should be a legislative priority. Whether in the state budget or in some other legislative vehicle, such as a supplemental budget, lawmakers should find a way to boost compensation rates across all categories of indigent defense, which span criminal, mental health, family law, and juvenile cases. Doing so would cost the state about $29 million annually. Advertisement Massachusetts' minimum bar advocate rate of $65 per hour is an outlier in New England. Maine's minimum rate is $150, New Hampshire's is $125 to $150, and Rhode Island's is $112 for most cases. Current rates in Massachusetts don't reflect the complexity of modern court cases, the overhead costs private attorneys pay out of pocket, or the state's sky-high cost of living. Advertisement The Senate's version of the budget does boost rates — but only for mental health appointments and Superior Court cases. The work stoppage is underscoring the critical work bar advocates produce. Since the stoppage began on May 27, the committee and its in-house counsel have struggled to provide attorneys for all clients that need them. Now, a slew of people accused of crimes are waiting, either in jails or out on bail — more than 150 people in Boston as of June 9, according to the Massachusetts Association of Criminal Defense Lawyers. These numbers are estimates, and bar advocate participation in the work stoppage varies between counties. But leaders agree that the number of unrepresented clients across Massachusetts is already in the hundreds and will continue to grow. Without representation, defendants are forced to stay in jail for days without arraignment, a violation of their constitutional rights. As early as next week, the Supreme Judicial Court may have to consider implementing the A shortage of bar advocates has put courts under pressure before. In 2019, Hampden County couldn't represent all of its clients, and a court instituted a day rate of $424 to incentivize additional private lawyers to handle arraignments. It was effective — and proved that low compensation really is a dissuasive factor for most private attorneys. Advertisement The legislature shouldn't wait for the crisis to deepen to provide a pay raise for bar advocates. Waiting to act will force more defendants to languish without representation, risking case mismanagement or pouring money into finding other private attorneys willing to do the work. This doesn't have to happen. The best way to solve this issue is to pay bar advocates fairly in the upcoming budget, allowing them to uphold the constitutional rights of their clients and ensuring due process across the Commonwealth. Editorials represent the views of the Boston Globe Editorial Board. Follow us
Yahoo
37 minutes ago
- Yahoo
Fapon Biopharma to Showcase Differentiated Pipeline, Including Phase 1 Immunocytokine FP008, and Innovative Technology Platforms at BIO 2025
BOSTON, June 12, 2025 /PRNewswire/ -- Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce its participation in the BIO International Convention 2025 (BIO 2025), taking place June 16-19 in Boston Convention & Exhibition Center. The company will exhibit at Booth #1851, presenting its differentiated pipeline, including the flagship Phase 1 immunocytokine FP008, a portfolio of promising early-stage candidates for oncology and autoimmune diseases, and its suite of proprietary technology platforms, while actively seeking global partnerships. FP008, Fapon Biopharma's lead asset, is a first-in-class immunocytokine currently in Phase 1 clinical trials, designed to address significant unmet needs in solid tumor patient refractory to anti-PD-1 therapy. The company will also feature promising preclinical candidates targeting oncology (FP010, FP011, FPE021) and autoimmune diseases (FPE022, FPE024), highlighting its expanding research capabilities. Fapon Biopharma will feature its proprietary and innovative technology platforms, engineered to overcome complex drug development challenges: Bi/Tri-TCE Platform: Human-monkey cross-reactive TCR/CD3 nanobody, enabling the design of potent multi-specific antibodies for targeted cancer immunotherapy. FILTEN™ (IL-10M Fusion Protein Platform): Overcoming IL-10 limitations for broad applications in cancer and autoimmune diseases PROTiNb™ (Proteolysis Targeting Intra-Nanobody): A pioneering platform targeting previously "undruggable" intracellular targets, demonstrating a strong competitive edge. FIND™ Mammalian Cell Display Platform: Accelerating antibody discovery by combining mammalian cell expression with high-throughput screening. "We are excited to connect with the global biopharma community at BIO 2025," said Vincent Huo, President of Fapon Biopharma. "We look forward to demonstrating the exciting progress of our internal pipeline and how our technology platforms can empower external partners to bring transformative therapy to patients faster." Engagement Opportunities:Exhibition Booth: #1851Company Presentation: Time: 11:30 a.m., Tuesday, June 17, 2025Location: Room 153A, Boston Convention & Exhibition Center To schedule a meeting in advance or during the conference, please contact our BD representatives, Max Wang ( and Liyan Gao ( or visit us at Booth #1851. Meetings can also be requested via the BIO partnering system. About Fapon Biopharma ( Fapon Biopharma specializes in discovering and developing biologics for treating cancers, autoimmune diseases and other diseases where there are unmet medical needs. Leveraging cutting-edge technologies, we have built advanced drug discovery platforms, including an antibody discovery platform based on the globally leading mammalian cell display technology, a platform for generating IL-10M fusion proteins, and a platform for developing multispecific antibodies using Fibody and nanobodies. With a differentiated pipeline of leading drug candidates, we have established capabilities that cover the entire drug development process from drug discovery, preclinical research, Chemistry, Manufacturing and Controls (CMC) to early clinical development. Committed to innovation, we strive to deliver safer, more efficacious, affordable, and accessible biologics for everyone. View original content to download multimedia: SOURCE Fapon Biopharma Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data